Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Journal Club
  • Published:

Does prefusion F protein-based respiratory syncytial virus immunization in pregnancy safely promote transplacental transfer of neutralizing antibodies?

Journal of Perinatology volume 44, pages 142–145 (2024)Cite this article

Subjects

Simões EAF, Center KJ, Tita ATN, Swanson KA, Radley D, Houghton J, McGrory SB, Gomme E, Anderson M, Roberts JP, Scott DA, Jansen KU, Gruber WC, Dormitzer PR, Gurtman AC. Prefusion F protein-based respiratory syncytial virus immunization in pregnancy. N Engl J Med. 2022; https://doi.org/10.1056/NEJMoa2106062 [1].

Do 120 or 240 micrograms (µg) of bivalent RSV prefusion F protein–based (RSVpreF) vaccine (with or without aluminum hydroxide) result in immunogenicity, transplacental transfer of RSV neutralizing antibodies, and have a safe profile compared to placebo?

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Data availability

All data supporting the findings of this manuscript are available within the paper and citations.

References

  1. Simões EAF, Center KJ, Tita ATN, Swanson KA, Radley D, Houghton J, et al. Prefusion F protein-based respiratory syncytial virus immunization in pregnancy. N Engl J Med. 2022;386:1615–26.

    Article  PubMed  Google Scholar 

  2. US Food and Drug Administration. Synagis; 2021. p. 1–15.

  3. American Academy of Pediatrics Committee on Infectious Diseases; American Academy of Pediatrics Bronchiolitis Guidelines Committee. Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection. Pediatrics. 2014;134:e620–38.

    Article  Google Scholar 

  4. O’Brien KL, Chandran A, Weatherholtz R, Jafri HS, Griffin MP, Bellamy T, et al. Efficacy of motavizumab for the prevention of respiratory syncytial virus disease in healthy native American infants: a phase 3 randomized double-blind placebo-controlled trial. Lancet Infect Dis. 2015;15:1398–408.

    Article  PubMed  Google Scholar 

  5. Shahabi A, Peneva D, Incerti D, McLaurin K, Stevens W. Assessing variation in the cost of palivizumab for respiratory syncytial virus prevention in preterm infants. Pharmacoecon Open. 2018;2:53–61.

    Article  PubMed  Google Scholar 

  6. Kim HW, Canchola JG, Brandt CD, Pyles G, Chanock RM, Jensen K, et al. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am J Epidemiol. 1969;89:422–34.

    Article  CAS  PubMed  Google Scholar 

  7. Mejias A, Garcia-Maurino C, Rodriguez-Fernandez R, Peeples ME, Ramilo O. Development and clinical applications of novel antibodies for prevention and treatment of respiratory syncytial virus infection. Vaccine. 2017;35:496–502.

    Article  CAS  PubMed  Google Scholar 

  8. Kampmann B, Madhi SA, Munjal I, Simões EAF, Pahud BA, Llapur C, et al. Bivalent prefusion F vaccine in pregnancy to prevent RSV illness in infants. N Engl J Med. 2023;388:1451–64.

    Article  CAS  PubMed  Google Scholar 

  9. Riffenburgh RH. Managing results of analysis. In: Statistics in Medicine, 3rd edition. San Diego, CA, USA: Academic Press; 2012. p. 325–43.

  10. Jennison C, Turnbull BW. Statistical approaches to interim monitoring of medical trials: a review and commentary. Stat Sci. 1990;5:299–317.

    Article  Google Scholar 

  11. Kumar A, Chakraborty BS. Interim analysis: a rational approach of decision making in clinical trial. J Adv Pharm Technol Res. 2016;7:118–22.

    Article  PubMed  PubMed Central  Google Scholar 

  12. Tyson JE, Pedroza C, Wallace D, D’Angio C, Bell EF, Das A. Stopping guidelines for an effectiveness trial: what should the protocol specify? Trials. 2016;17:240.

    Article  PubMed  PubMed Central  Google Scholar 

  13. Guyatt GH, Briel M, Glasziou P, Bassler D, Montori VM. Problems of stopping trials early. BMJ Br Med J. 2012;344:e3863.

    Article  Google Scholar 

  14. Bassler D, Montori VM, Briel M, Glasziou P, Guyatt G. Early stopping of randomized clinical trials for overt efficacy is problematic. J Clin Epidemiol. 2008;61:241–6.

    Article  PubMed  Google Scholar 

  15. Lewis RJ. An introduction to the use of interim data analyses in clinical trials. Ann Emerg Med. 1993;22:1463–9.

    Article  CAS  PubMed  Google Scholar 

  16. Fisher JG, Jones BA, Gutierrez IM, Hull MA, Kang KH, Kenny M, et al. Mortality associated with laparotomy-confirmed neonatal spontaneous intestinal perforation: a prospective 5-year multicenter analysis. J Pediatr Surg. 2014;49:1215–9.

    Article  PubMed  Google Scholar 

  17. Chen D-T, Schell MJ, Fulp WJ, Pettersson F, Kim S, Gray JE, et al. Application of Bayesian predictive probability for interim futility analysis in single-arm phase II trial. Transl Cancer Res. 2019;8:S404–20.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Pedroza C, Tyson JE, Das A, Laptook A, Bell EF, Shankaran S. Advantages of Bayesian monitoring methods in deciding whether and when to stop a clinical trial: an example of a neonatal cooling trial. Trials. 2016;17:335.

    Article  PubMed  PubMed Central  Google Scholar 

  19. Ryan EG, Brock K, Gates S, Slade D. Do we need to adjust for interim analyses in a Bayesian adaptive trial design? BMC Med Res Methodol. 2020;20:150.

    Article  PubMed  PubMed Central  Google Scholar 

  20. Friedman LM, Furberg CD, DeMets DL, Reboussin DM, Granger CB. Statistical methods used in interim monitoring. fundamentals of clinical trials. Springer; 2015. p. 373–401.

    Chapter  Google Scholar 

Download references

Acknowledgements

The Journal Club is a collaboration between the American Academy of Pediatrics - Section of Neonatal Perinatal Medicine and the International Society for Evidence-Based Neonatology (EBNEO.org).

Author information

Authors and Affiliations

  1. Department of Pediatrics, Division of Neonatology, Nationwide Children’s Hospital, The Ohio State University College of Medicine, Columbus, OH, USA

    Allison C. Lure, Pablo J. Sánchez & Jonathan L. Slaughter

  2. Department of Pediatrics, Division of Infectious Disease, Nationwide Children’s Hospital, Columbus, OH, USA

    Pablo J. Sánchez

  3. Center for Perinatal Research, The Abigail Wexner Research Institute at Nationwide Children’s Hospital, Columbus, OH, USA

    Pablo J. Sánchez & Jonathan L. Slaughter

  4. Division of Epidemiology, The Ohio State University College of Public Health, Columbus, OH, USA

    Jonathan L. Slaughter

Authors
  1. Allison C. Lure
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Pablo J. Sánchez
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jonathan L. Slaughter
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

ACL conceived the analysis, wrote the first draft, and finalized the paper. PJS contributed ideas in the summary of the article analyzed, and reviewed and edited the paper. JLS contributed ideas in the “Commentary” and “EBM Lesson” sections and reviewed and edited the paper. All authors reviewed and approved the final version of the manuscript.

Corresponding author

Correspondence to Allison C. Lure.

Ethics declarations

Competing interests

The authors declare no competing interests.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Lure, A.C., Sánchez, P.J. & Slaughter, J.L. Does prefusion F protein-based respiratory syncytial virus immunization in pregnancy safely promote transplacental transfer of neutralizing antibodies?. J Perinatol 44, 142–145 (2024). https://doi.org/10.1038/s41372-023-01769-3

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41372-023-01769-3

Search

Advanced search

Quick links